Table 3.

Champalimaud Clinical Centre (DaT-SPECT) cohort demographics

	Positive	Negative	P-value
n	34 (39.5%)	52 (60.5%)
Age (yr)	65.1 (10.2)	65.1 (14.9)	0.988
Female, n (%)	21 (61.8)	31 (60.8)	1.000
DA treatment, n (%)	17 (50.0)	8 (16.0)	0.002*
Tremor treatment, n (%)	1 (2.9)	13 (26.0)	0.013*
LEDD (mg/day)	183.8 (295.2)	51.6 (138.7)	0.021*
Symptom onset (months)	43.3 (70.1)	41.2 (51.1)	0.884
MDS-UPDRS III Total	21.4 (14.7)	14.2 (12.2)	0.021*
Rigidity	2.9 (2.7)	1.1 (1.6)	0.001*
Bradykinesia	11.3 (8.5)	7.4 (7.2)	0.031*
Rest tremor	1.1 (1.7)	0.7 (1.2)	0.270
Tremor	3.2 (3.6)	3.2 (4.0)	0.976

DA dopamine, LEDD Levodopa Equivalent Daily Dose, MDS-UPDRS Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale. *P < 0.05.